Savient sells gout med to Crealta

Share this article:

Pending court approval, Savient's orphan drug Krystexxa will join Crealta Pharmaceuticals' drug portfolio.

Savient announced the deal for its refractory chronic gout medication Wednesday.

The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.